Soligenix Inc. (NASDAQ: SNGX), a biopharmaceutical company specializing in rare diseases, is set to reach several critical milestones in 2025, according to a recent Zacks Small-Cap Research report. The company's phase 3 FLASH2 trial for HyBryte(TM), aimed at treating early-stage cutaneous T cell lymphoma (CTCL), is among the key developments expected to provide updates on enrollment in the latter half of 2025, with topline results anticipated in 2026.
Further clinical updates are expected in the third quarter of 2025 for an investigator-initiated study evaluating extended HyBryte(TM) treatment. Additionally, Soligenix is looking forward to topline results from its phase 2a trials for SGX302 in mild-to-moderate psoriasis and SGX945 in Behcet’s disease. These developments underscore Soligenix's commitment to addressing unmet medical needs in rare diseases.
The Zacks report expresses optimism about Soligenix's upcoming catalysts, particularly the FLASH2 trial, based on promising interim results. The company's progress in its psoriasis and Behcet’s disease programs also presents potential upside not currently reflected in its share price. For more details, the full report can be accessed here.
